The effects of semi- and HPLC-purified XXXX satietin and alpha-1-glycoprotein on ingestion and body weight.

@entity35 @entity1 @entity6614
Satietin is thought to be an endogenous glycoprotein that can suppress food intake (FI) and body weight (b.wt.). In Experiment 1, @entity35 were ICV infused with either a-CSF or with 50 micrograms/ @entity35 of @entity1 satietin. FI was suppressed (p less than 0.05) for 2 days after infusion, whereas b.wt. was attenuated (p less than 0.05) for 14 days. In Experiment 2, the previously thought homogenous @entity1 satietin was further purified by HPLC and this yielded two peaks (A and @entity35 were ICV infused with either a-CSF or 50 micrograms/ @entity35 of Peak A, Peak B or the semipurified parent @entity1 satietin (sph-SAT) from which the peaks were derived. All three treatments suppressed (p less than 0.05) FI on day 1 after infusion and on day 2 in the groups that received Peak A and sph-SAT. Body weight was attenuated (p less than 0.01) in all the experimental groups on day 1 and for 2 and 10 days, respectively, in the Peak A and sph-SAT-treated groups. Immunostaining revealed Peak A contained both albumin and alpha-1-glycoprotein ( @entity6614 ), whereas Peak B contained neither. In the last experiment @entity35 were ICV infused with either a-CSF or 50 micrograms/ @entity35 of @entity6614 or @entity6614 that was put through the sph-SAT extraction procedure. FI was suppressed (p less than 0.01) and b.wt. attenuated in both experimental groups only on the first day postinfusion. These data suggest that some, but possibly not all, of the previously found biological activity attributed to sph-SAT might be due to contaminants of the preparation.
